We developed a 2-step approach to myeloablative haploidentical HSCT in which patients receive a large fixed dose of cyclophosphamide (CY)-tolerized T cells separately frm the HSC infusion in the hopes of accelerating post HSCT immune reconstitution (IR). The uniformity of the T cell dosing facilitates comparison of patients without (low risk) and with (high risk) active malignancy at HSCT to ascertain the impact of disease status at HSCT on IR with fewer confounding effects from conditioning or T cell dosing.
Gaballa, Sameh; Alpdogan, Onder; Carabasi, Matthew; Filicko, Joanne; Kasner, Margaret; Martinez-Outshoorn, MD, Ubaldo E.; Wagner, John L; Weiss, Mark; Flomenberg, Neal; and Grosso, Delores, "A 2-Step Approach to Myeloablative Haploidentical Stem Cell Transplantation with Optimized T-Cell Dosing: Early Immune Reconstitution Leads to Better Outcomes" (2013). Department of Medical Oncology Faculty Papers. Paper 16.